{"id":741997,"date":"2025-05-05T17:28:02","date_gmt":"2025-05-05T17:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=741997"},"modified":"2025-05-05T17:28:02","modified_gmt":"2025-05-05T17:28:02","slug":"bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies_741997.html","title":{"rendered":"Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/05\/1746447101.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/05\/1746447101.jpg\" alt=\"Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong> &ldquo;Bronchitis Pipeline Insight 2025&rdquo;<\/strong> report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the Bronchitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bronchitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the comprehensive insights by DelveInsight and stay ahead in understanding the C Bronchitis Treatment Landscape. Click here to read more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bronchitis Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Bronchitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>In April 2025, Incyte Corporation<\/em><\/strong> announced a study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).<\/li>\n<li><strong><em>In April 2025, Kadmon, a Sanofi Company<\/em><\/strong> announced a Phase 2, open-label, long-term treatment and follow-up study in subjects with cGVHD who have been previously treated with belumosudil in Study KD025-208 or Study KD025-213. Subjects will not be screened.<\/li>\n<li>DelveInsight&rsquo;s Bronchitis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchitis treatment.<\/li>\n<li>The leading Bronchitis Companies such as <strong><em>Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp &amp; Dohme Corp., Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott<\/em><\/strong> and others.<\/li>\n<li>Promising Bronchitis Pipeline Therapies such as <strong><em>BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover groundbreaking developments in Bronchitis Therapies! Gain in-depth knowledge of key Bronchitis Clinical trials, emerging drugs, and market opportunities @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bronchitis Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bronchitis Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>DW 1601: Daewon Pharmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Daewon Pharmaceutical is developing DW 1601 for the treatment of Bronchitis.<\/p>\n<p style=\"text-align: justify;\"><strong>The Bronchitis Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Bronchitis with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchitis Treatment.<\/li>\n<li>Bronchitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Bronchitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchitis Market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the Bronchitis Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bronchitis Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bronchitis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp &amp; Dohme Corp., Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Infusion<\/li>\n<li>Intradermal<\/li>\n<li>Intramuscular<\/li>\n<li>Intranasal<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Bronchitis Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vaccines<\/li>\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Transform your understanding of the Bronchitis Pipeline! See the latest progress in drug development and clinical research @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bronchitis Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Bronchitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Bronchitis Companies- <strong><em>Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp &amp; Dohme Corp., Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott<\/em><\/strong> and others.<\/li>\n<li>Bronchitis Pipeline Therapies- <strong><em>BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids<\/em><\/strong> and others.<\/li>\n<li>Bronchitis Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Bronchitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay Ahead in Respiratory Disease Research&ndash;Access the Full Bronchitis Pipeline Analysis Today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bronchitis Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Bronchitis: Overview<\/li>\n<li>Causes<\/li>\n<li>Mechanism of Action<\/li>\n<li>Signs and Symptoms<\/li>\n<li>Diagnosis<\/li>\n<li>Disease Management<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Comparative Analysis<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Assessment by Product Type<\/li>\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type<\/li>\n<li>Bronchitis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Bronchitis companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/li>\n<li>Bronchitis Collaboration Deals<\/li>\n<li>Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/li>\n<li>Company-University Collaborations (Licensing \/ Partnering) Analysis<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Comparative Analysis<\/li>\n<li>DW 1601: Daewon Pharmaceutical<\/li>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Comparative Analysis<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Comparative Analysis<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Comparative Analysis<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Comparative Analysis<\/li>\n<li>Bronchitis Key Companies<\/li>\n<li>Bronchitis Key Products<\/li>\n<li>Bronchitis- Unmet Needs<\/li>\n<li>Bronchitis- Market Drivers and Barriers<\/li>\n<li>Bronchitis- Future Perspectives and Conclusion<\/li>\n<li>Bronchitis Analyst Views<\/li>\n<li>Bronchitis Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Bronchitis Pipeline Insight 2025&rdquo; report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the Bronchitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bronchitis Pipeline Therapeutics &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies_741997.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406],"tags":[],"class_list":["post-741997","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/741997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=741997"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/741997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=741997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=741997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=741997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}